Sifalimumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Sifalimumab
Monoclonal antibody
Type Whole antibody
Source Human
Target Interferon α
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
Formula C6518H10008N1724O2032S38
Molar mass 146.25 kg/mol
 NYesY (what is this?)  (verify)

Sifalimumab is a human monoclonal antibody designed for the treatment of SLE, dermatomyositis, and polymyositis. It targets interferon a.[1]

Sifalimumab was developed by MedImmune.

References[edit]

  1. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Sifalimumab" (PDF). American Medical Association.